DE69909970D1 - Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten - Google Patents

Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Info

Publication number
DE69909970D1
DE69909970D1 DE69909970T DE69909970T DE69909970D1 DE 69909970 D1 DE69909970 D1 DE 69909970D1 DE 69909970 T DE69909970 T DE 69909970T DE 69909970 T DE69909970 T DE 69909970T DE 69909970 D1 DE69909970 D1 DE 69909970D1
Authority
DE
Germany
Prior art keywords
trifluoromethoxybenzothiazol
amino
preventing
production
medicinal product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69909970T
Other languages
English (en)
Other versions
DE69909970T2 (de
Inventor
Andrees Bohme
Alain Boireau
Thierry Canton
Assunta Imperato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Aventis Pharma SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA
Publication of DE69909970D1 publication Critical patent/DE69909970D1/de
Application granted granted Critical
Publication of DE69909970T2 publication Critical patent/DE69909970T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE69909970T 1998-02-06 1999-02-03 Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten Expired - Lifetime DE69909970T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9801402 1998-02-06
FR9801402A FR2774592B1 (fr) 1998-02-06 1998-02-06 Application du 2-amino-6-trifluoromethoxybenzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet
PCT/FR1999/000230 WO1999039710A1 (fr) 1998-02-06 1999-02-03 Application du 2-amino-6- trifluoromethoxy- benzothiazole pour la prevention ou le traitement des dysfonctionnements du cervelet

Publications (2)

Publication Number Publication Date
DE69909970D1 true DE69909970D1 (de) 2003-09-04
DE69909970T2 DE69909970T2 (de) 2004-05-27

Family

ID=9522673

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69909970T Expired - Lifetime DE69909970T2 (de) 1998-02-06 1999-02-03 Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten

Country Status (18)

Country Link
US (1) US6245791B1 (de)
EP (1) EP1052989B1 (de)
JP (1) JP5127092B2 (de)
KR (1) KR100574378B1 (de)
AT (1) ATE245982T1 (de)
AU (1) AU761978B2 (de)
CA (1) CA2319686C (de)
DE (1) DE69909970T2 (de)
DK (1) DK1052989T3 (de)
EA (1) EA002676B1 (de)
ES (1) ES2199541T3 (de)
FR (1) FR2774592B1 (de)
IL (2) IL137608A0 (de)
NO (1) NO327819B1 (de)
NZ (1) NZ506124A (de)
PT (1) PT1052989E (de)
WO (1) WO1999039710A1 (de)
ZA (1) ZA99740B (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872739B1 (en) * 1999-06-04 2005-03-29 Vereniging Voor Christelijk Wetenshappelikjk Onderwijs Use of riluzole for the treatment of multiple sclerosis
SG11202011187QA (en) * 2018-05-27 2020-12-30 Biohaven Pharm Holding Co Ltd Use of riluzole oral disintigrating tablets for treating diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0374041B1 (de) * 1988-12-15 1992-06-17 Rhone-Poulenc Sante 2-Benzothiazolamin-Derivate enthaltende Arzneimittel, Verbindungen und ihre Herstellung
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
FR2702148B1 (fr) * 1993-03-05 1995-04-07 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement du neuro-sida.
FR2714828B1 (fr) * 1994-01-12 1996-02-02 Rhone Poulenc Rorer Sa Application du riluzole dans le traitement des maladies mitochondriales.
FR2726271B1 (fr) * 1994-10-26 1996-12-06 Rhone Poulenc Rorer Sa Derives de 6-polyfluoroalcoxy-2-aminobenzothiazole

Also Published As

Publication number Publication date
NO327819B1 (no) 2009-09-28
WO1999039710A1 (fr) 1999-08-12
CA2319686C (fr) 2009-06-23
US6245791B1 (en) 2001-06-12
DK1052989T3 (da) 2003-11-17
NZ506124A (en) 2003-07-25
ATE245982T1 (de) 2003-08-15
JP2002502819A (ja) 2002-01-29
JP5127092B2 (ja) 2013-01-23
AU2171199A (en) 1999-08-23
AU761978B2 (en) 2003-06-12
NO20003785L (no) 2000-07-24
EA200000816A1 (ru) 2001-02-26
EA002676B1 (ru) 2002-08-29
ES2199541T3 (es) 2004-02-16
ZA99740B (en) 1999-08-02
NO20003785D0 (no) 2000-07-24
FR2774592B1 (fr) 2000-03-17
CA2319686A1 (fr) 1999-08-12
IL137608A (en) 2006-09-05
EP1052989A1 (de) 2000-11-22
KR100574378B1 (ko) 2006-04-26
EP1052989B1 (de) 2003-07-30
IL137608A0 (en) 2001-07-24
FR2774592A1 (fr) 1999-08-13
PT1052989E (pt) 2003-12-31
DE69909970T2 (de) 2004-05-27
KR20010040671A (ko) 2001-05-15

Similar Documents

Publication Publication Date Title
GB0223038D0 (en) Therapeutic compounds
BR9502707A (pt) Composto composição farmacêutica e método para o tratamento de uma afecção
DE69428268T2 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
GB0225474D0 (en) Therapeutic agents
GB0225475D0 (en) Therapeutic agents
ATE205086T1 (de) Verwendung von dem chelatbildner clioquinol zur herstellung eines arzneimittelszur behandlung von alzheimerschen krankheit
MXPA04003245A (es) Hidroxipropilaminas.
ATE335487T1 (de) Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
WO2004006849A3 (en) Combinations of drugs for the treatment of neoplasms
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE69909970D1 (de) Verwendung von 2-amino-6-trifluoromethoxybenzothiazol zur herstellung eines arzneimittels zur vorbeugung oder behandlung von zerebellumkrankheiten
ATE294582T1 (de) Verwendung von alpha-1-adrenorezeptor- antagonisten zur herstellung eines medikaments für die vorbeugung und die behandlung von krebs
ATE247956T1 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
ATE492285T1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE324111T1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
AU2003286118A1 (en) Novel chelidonine derivatives, methods for the production thereof, and use thereof for producing pharmaceutical agents
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE69610045T2 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
ATE257702T1 (de) Verwendung von 2-imidazolyl-substituierten carbinolen zur herstellung eines medikaments zur behandlung oder prophylaxe von durch ischämischen zuständen bewirkten krankheiten
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
ATE186640T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung neurogenerativer erkrankungen
HK1080768A1 (en) Use of epothilone derivatives for the treatment ofhyperparathyroidism
ATE201993T1 (de) Verwendung von olanzapine zur herstellung eines arzneimittels zur behandlung der zerebralen fokalen ischämie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: PFENNING MEINIG & PARTNER GBR, 80339 MUENCHEN

8328 Change in the person/name/address of the agent

Representative=s name: MAIWALD PATENTANWALTSGESELLSCHAFT MBH, 80335 MUENC